Disentangling Pharmacological and Expectation Effects in Antidepressant Discontinuation
NCT05191277 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56
Last updated 2026-05-18
Summary
Antidepressant medication is established as an evidence-based, guideline-recommended treatment for Major Depressive Disorders. In the past decades, prescriptions of antidepressant medication have markedly increased, with a specific surge in maintenance prescriptions and therefore, long-term intake, despite guideline recommendations to discontinue antidepressant medication after maintenance therapy has been completed.
Over half of fully remitted patients who attempt to discontinue their antidepressant medication report adverse discontinuation symptoms. For many patients, discontinuation symptoms are so severe, that they do not manage to complete their discontinuation attempt. While discontinuation symptoms, deterioration of depressive symptoms, and recurrence can result from pharmacological effects of antidepressant discontinuation, patients' expectations towards discontinuation are likely to play an essential role in occurrence, too.
The aim of the present study is to explore the interplay of expectations and pharmacological effects in antidepressant discontinuation. Participants who fulfill German national S3 guideline recommendations will receive a 1:1 chance to either discontinue their antidepressant medication or remain on their antidepressant medication. In addition, participants' expectations are intended to be manipulated by varying verbal instructions using the open-hidden paradigm. Within the open trial arms, participants will receive full information about their treatment (i.e., high expectation). Within the hidden trial arms, participants will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation). Participants will have a 1:1:1:1 chance of being allocated to 1 of the 4 experimental groups: open discontinuation (OD), hidden discontinuation (HD), open continuation (OC), or hidden continuation (HC) of their antidepressant medication.
This preregistration is part of the collaborative research center (CRC) SFB/TRR289 which aims to characterize the psychological and neurobiological effects of treatment expectations on health outcome (https://treatment-expectation.de) and is funded by the Deutsche Forschungsgemeinschaft (DFG).
Conditions
- Depressive Symptoms
- Expectations
- Antidepressants
Interventions
- DRUG
-
Treatment 'discontinuation of antidepressant medication'
Pharmacological intervention: Participants will discontinue their antidepressant medication.
- DRUG
-
Treatment 'continuation of antidepressant medication'
Pharmacological intervention: Participants will remain on their antidepressant medication.
- BEHAVIORAL
-
Expectation 'high'
Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the open trial arms, participants will receive full information about their treatment (i.e., high expectation). expectation).
- BEHAVIORAL
-
Expectation 'moderate'
Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the hidden trial arms, participants will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
Sponsors & Collaborators
-
Philipps University Marburg
collaborator OTHER -
Helmut Schmidt University
collaborator OTHER -
University Hospital, Essen
collaborator OTHER -
Universitätsklinikum Hamburg-Eppendorf
lead OTHER
Principal Investigators
-
Yvonne Nestoriuc, Prof. Dr. · Universitätsklinikum Hamburg-Eppendorf
-
Tilo Kircher, Prof. Dr. · Philipps University Marburg
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-08-01
- Primary Completion
- 2025-02-26
- Completion
- 2025-11-26
Countries
- Germany
Study Locations
More Related Trials
-
Benefits of Switching Antidepressants Following Early Nonresponse
NCT00519012 ·Status: UNKNOWN ·Phase: PHASE4
-
Tapering Off Antidepressants
NCT02661828 ·Status: TERMINATED ·Phase: NA
-
Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD
NCT00433121 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacological Intervention Project (Fluoxetine)
NCT00027378 ·Status: COMPLETED ·Phase: PHASE2
-
Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents
NCT00332787 ·Status: COMPLETED ·Phase: NA
-
Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms
NCT00578669 ·Status: COMPLETED ·Phase: PHASE3
-
Neurobiological and Genomic Predictors of Relapse in Depression
NCT07328373 ·Status: RECRUITING
-
Treatment of Mild and Subthreshold Depressive Disorders
NCT00226642 ·Status: UNKNOWN ·Phase: PHASE4
-
Interpersonal Psychotherapy for Severely Depressed Inpatients
NCT00325000 ·Status: TERMINATED ·Phase: NA
-
Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents
NCT00249886 ·Status: WITHDRAWN ·Phase: PHASE3
-
Determinants in Antidepressant Outcomes
NCT00108316 ·Status: WITHDRAWN ·Phase: NA
-
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
NCT04532749 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Fluoxetine in Adults With Autistic Disorder
NCT00027404 ·Status: COMPLETED ·Phase: NA
-
Mindfulness Based Cognitive Therapy and Antidepressant Medication in Recurrent Depression
NCT00928980 ·Status: COMPLETED ·Phase: NA
-
Serotonin and Everyday Social Interaction
NCT02051569 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Antidepressant Maintenance in Traumatic Brain Injury
NCT00162916 ·Status: UNKNOWN ·Phase: PHASE4
-
Mood, Serotonin and Social Interaction
NCT02051530 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Can Additional Drug Therapy Accelerate Response Time to Antidepressants
NCT00221494 ·Status: WITHDRAWN ·Phase: PHASE4
-
The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
NCT00581009 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder
NCT04451187 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning
NCT00611975 ·Status: COMPLETED ·Phase: PHASE4
-
Cognitive Therapy for Recurrent Depression
NCT00118404 ·Status: COMPLETED ·Phase: PHASE3
-
The Metabolic Effects of Antidepressants in Patients Diagnosed With Major Depressive Disorder
NCT01418638 ·Status: UNKNOWN
-
Pharmacogenetics of Antidepressant-Induced Disinhibition
NCT03953014 ·Status: RECRUITING
-
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
NCT01919216 ·Status: COMPLETED ·Phase: PHASE4